Alluvi tirzepatide has been emerged as a promising therapeutic agent for the control of metabolic diseases. This initial evaluation investigated the efficacy and profile of tirzepatide 40mg in in vivo models of metabolic syndrome. The experiments demonstrated that tirzepatide 40mg significantly improved glycemic management and decreased insulin sen